[
  {
    "ts": "2025-11-21T00:20:15+00:00",
    "headline": "Evaluating Eli Lilly Shares After 30% Surge Driven by Obesity Drug Pipeline News",
    "summary": "Curious whether Eli Lilly’s stock is still a smart buy after its rapid rise? Let’s break down the numbers and see if the current price matches up with real value. Shares have vaulted higher lately, climbing 30.5% in just the last month and notching a stunning 40.2% gain over the past year. Investors are watching Eli Lilly closely after headline-making developments in its obesity and diabetes drug pipeline sent the stock to new highs. This reflects excitement over blockbuster potential and...",
    "url": "https://finance.yahoo.com/news/evaluating-eli-lilly-shares-30-002015560.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1b85e004-fb57-39e6-ae95-5104ec899927",
      "content": {
        "id": "1b85e004-fb57-39e6-ae95-5104ec899927",
        "contentType": "STORY",
        "title": "Evaluating Eli Lilly Shares After 30% Surge Driven by Obesity Drug Pipeline News",
        "description": "",
        "summary": "Curious whether Eli Lilly’s stock is still a smart buy after its rapid rise? Let’s break down the numbers and see if the current price matches up with real value. Shares have vaulted higher lately, climbing 30.5% in just the last month and notching a stunning 40.2% gain over the past year. Investors are watching Eli Lilly closely after headline-making developments in its obesity and diabetes drug pipeline sent the stock to new highs. This reflects excitement over blockbuster potential and...",
        "pubDate": "2025-11-21T00:20:15Z",
        "displayTime": "2025-11-21T00:20:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evaluating-eli-lilly-shares-30-002015560.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evaluating-eli-lilly-shares-30-002015560.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T00:01:48+00:00",
    "headline": "Analysts get more bullish on this non-tech stock",
    "summary": "The market has been swinging recently, with the S&P 500 index down 1.5% and the Nasdaq Composite down more than 2% over the past month. Investors are now questioning whether the tech momentum can continue. Some non-tech stocks have performed well, and Eli Lilly (LLY) is one of them. Eli ...",
    "url": "https://www.thestreet.com/investing/stocks/analysts-get-more-bullish-on-this-non-tech-stock",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "4dee68ca-7a8f-3259-9326-a2642b37c982",
      "content": {
        "id": "4dee68ca-7a8f-3259-9326-a2642b37c982",
        "contentType": "STORY",
        "title": "Analysts get more bullish on this non-tech stock",
        "description": "",
        "summary": "The market has been swinging recently, with the S&P 500 index down 1.5% and the Nasdaq Composite down more than 2% over the past month. Investors are now questioning whether the tech momentum can continue. Some non-tech stocks have performed well, and Eli Lilly (LLY) is one of them. Eli ...",
        "pubDate": "2025-11-21T00:01:48Z",
        "displayTime": "2025-11-21T00:01:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/736620a120e40adbbc536cd4720f4c7b",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F_cqr7ObVav9uUsiftVcrg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/736620a120e40adbbc536cd4720f4c7b.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vxESFjJPSwfyMp50xsym3Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/736620a120e40adbbc536cd4720f4c7b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/investing/stocks/analysts-get-more-bullish-on-this-non-tech-stock",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-more-bullish-non-tech-000148985.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T13:00:00+00:00",
    "headline": "9amHealth to Expand Access to Obesity Management Treatment through New Employer Health Benefits Offering",
    "summary": "9amHealth, a leader in virtual cardiometabolic care, today announced a new offering designed to make access to obesity management medications and care more sustainable for employers. The \"No-Barriers Bundle\" offers access to FDA-approved obesity medicines from Eli Lilly and Company (Lilly) and Novo Nordisk, along with 9amHealth's comprehensive cardiometabolic care program, creating a transparent, cost-efficient pathway for employers to support their teams' health.",
    "url": "https://finance.yahoo.com/news/9amhealth-expand-access-obesity-management-130000751.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "84991737-6937-3dd6-8a52-d51b4cf1ad8a",
      "content": {
        "id": "84991737-6937-3dd6-8a52-d51b4cf1ad8a",
        "contentType": "STORY",
        "title": "9amHealth to Expand Access to Obesity Management Treatment through New Employer Health Benefits Offering",
        "description": "",
        "summary": "9amHealth, a leader in virtual cardiometabolic care, today announced a new offering designed to make access to obesity management medications and care more sustainable for employers. The \"No-Barriers Bundle\" offers access to FDA-approved obesity medicines from Eli Lilly and Company (Lilly) and Novo Nordisk, along with 9amHealth's comprehensive cardiometabolic care program, creating a transparent, cost-efficient pathway for employers to support their teams' health.",
        "pubDate": "2025-11-21T13:00:00Z",
        "displayTime": "2025-11-21T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/0ff63062325cfc78d093cd96f33bfe41",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "(PRNewsfoto/9am.health Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/awWWj1Z4pRyVuwbWoyVm9g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0ff63062325cfc78d093cd96f33bfe41.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MgpCPssgeKAWHmaVPDccng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0ff63062325cfc78d093cd96f33bfe41.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/9amhealth-expand-access-obesity-management-130000751.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/9amhealth-expand-access-obesity-management-130000751.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T13:53:50+00:00",
    "headline": "Update: Market Chatter: Eli Lilly, Novo Nordisk to Offer GLP-1 Drugs Direct to Employers",
    "summary": "(Updates to add Waltz Health's comment in the seventh and eighth paragraphs.) Eli Lilly (LLY) and",
    "url": "https://finance.yahoo.com/news/market-chatter-eli-lilly-novo-135350521.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "937d7575-16e2-3305-8c53-1405928c8224",
      "content": {
        "id": "937d7575-16e2-3305-8c53-1405928c8224",
        "contentType": "STORY",
        "title": "Update: Market Chatter: Eli Lilly, Novo Nordisk to Offer GLP-1 Drugs Direct to Employers",
        "description": "",
        "summary": "(Updates to add Waltz Health's comment in the seventh and eighth paragraphs.) Eli Lilly (LLY) and",
        "pubDate": "2025-11-21T13:53:50Z",
        "displayTime": "2025-11-21T13:53:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-eli-lilly-novo-135350521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-eli-lilly-novo-135350521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T13:27:15+00:00",
    "headline": "Market Chatter: Eli Lilly, Novo Nordisk to Offer GLP-1 Drugs Direct to Employers",
    "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) are set to begin offering their popular GLP-1 medications to",
    "url": "https://finance.yahoo.com/news/market-chatter-eli-lilly-novo-132715677.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "3ae0f616-55e0-354d-8bec-fd8ef0abb207",
      "content": {
        "id": "3ae0f616-55e0-354d-8bec-fd8ef0abb207",
        "contentType": "STORY",
        "title": "Market Chatter: Eli Lilly, Novo Nordisk to Offer GLP-1 Drugs Direct to Employers",
        "description": "",
        "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) are set to begin offering their popular GLP-1 medications to",
        "pubDate": "2025-11-21T13:27:15Z",
        "displayTime": "2025-11-21T13:27:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-eli-lilly-novo-132715677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-eli-lilly-novo-132715677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T14:00:00+00:00",
    "headline": "Ilant Health Enhances Comprehensive Cardiometabolic Care with Direct Contracting for Obesity Management Medicine for Employers",
    "summary": "NEW YORK, November 21, 2025--Ilant Health announced that it will offer employers direct contracting and transparent pricing of Eli Lilly and Company (Lilly) obesity management medicines.",
    "url": "https://finance.yahoo.com/news/ilant-health-enhances-comprehensive-cardiometabolic-140000189.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "765c7b76-cca4-3af7-b887-fd0015aa0a81",
      "content": {
        "id": "765c7b76-cca4-3af7-b887-fd0015aa0a81",
        "contentType": "STORY",
        "title": "Ilant Health Enhances Comprehensive Cardiometabolic Care with Direct Contracting for Obesity Management Medicine for Employers",
        "description": "",
        "summary": "NEW YORK, November 21, 2025--Ilant Health announced that it will offer employers direct contracting and transparent pricing of Eli Lilly and Company (Lilly) obesity management medicines.",
        "pubDate": "2025-11-21T14:00:00Z",
        "displayTime": "2025-11-21T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ilant-health-enhances-comprehensive-cardiometabolic-140000189.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ilant-health-enhances-comprehensive-cardiometabolic-140000189.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]